Juvaderm Now

Juvaderm, or more correctly, Juvederm, is a gel made from hyaluronic acid - a natural substance in the skin which helps to hydrate and add volume to the skin. Hyaluronic acid is the main component of the extracellular matrix, i.e., tissue which provides structural support to your cells. Hyaluronic acid gives tissue the ability to resist compression by providing a counteracting turgor (swelling) force by absorbing a lot of water. Juvaderm (or Juvederm) is made by a company called Allergen, Inc., a global pharmaceutical company based in Irvine, California. The company is listed on the New York Stock Exchange. It earns revenues totalling US$3.9 billion during the 2007 financial year. Allergan’s manufacturing plants are located in cities such as Waco in Texas, Westport in Ireland and San Jose in Costa Rica. The company also manufactures other popular products such as Botox, a neurotoxic protein which temporarily smooths frown lines.

On 5 June 2006, the U.S. Food and Drug Administration (FDA) first approved the Juvaderm/Juvederm dermal filler gel family of products. These gels represented a ‘next generation’ of hyaluronic acid dermal fillers that provide a smooth and long-lasting correction of facial wrinkles and folds. About 4 months later, on 26 September 2006, Allergan announced the launch of two new products, Juvéderm™ Ultra and Juvéderm™ Ultra Plus. But the product was not to be made available to the nation just yet. It was made available on a selective basis, through “experience” trials conducted by physicians with expertise in facial aesthetics. The Juvaderm/Juvederm experience trial involved physicians testing the Juvaderm products on willing participants at a various centers. The experience trial was designed to gain relevant information on physicians’ use of Juvéderm™ Ultra and Juvéderm™ Ultra Plus and evaluate the persistence of and patient satisfaction with the products in daily clinical practice. Juvéderm™ Ultra and Juvéderm™ Ultra Plus became available nationwide in the U.S. on 17 January 2007.

On 26 June 2007, Allergan announced that the FDA had approved label extensions for its Juvaderm/Juvederm products. The approval was given based on new clinical data which demonstrated that the effects of both Juvéderm™ Ultra and Juvéderm™ Ultra Plus could last for up to 1 year, which was longer than reported in clinical studies which supported FDA approval of other hyaluronic acid dermal fillers. This result generated a favourable response from both patients and physicians alike as many want fillers that are long-lasting and still reversible – now people could obtain a natural look that could still be adjustable over time as the face changed with age. Such features were not so readily available with the existing semi-permanent or permanent products in the market.

Tags: Juvaderm, Juvederm, what is Juvaderm, what is Juvederm

No related posts.

Tags: juvaderm | Juvederm | what is Juvaderm | what is Juvederm

You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.